FP03.04 Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Conversion and Proliferation

The use of immune-checkpoint inhibitors (ICI) has greatly improved the outcome of patients with NSCLC. However, only 30-40% of patients benefit from this therapy and many of them develop acquired resistance. Immunomodulatory drugs that can reinvigorate the immune cytotoxic activity in combination with ICI (such as anti-PD-1) are a great promise to overcome resistance and improve the response to immunotherapy. Here, we evaluated the prognostic value of the SRC family kinases (SFKs), with special focus on YES1, and the immunomodulatory effect of the SFKs inhibitor, dasatinib, in combination with anti-PD-1, in two clinically relevant mouse models of NSCLC.